Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT-333 in Relapsed/Refractory Lymphomas, Leukemias, and Solid Tumors
NCT05225584Phase 1Completed
- Sponsor
- Kymera Therapeutics
- Start
- May 2022
- Primary completion
- Mar 2025
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label trial of lirodegimod in non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), large granular lymphocytic leukemia (LGLL) and 4 more (8 arms), sponsored by Kymera Therapeutics. Primary endpoints: Safety (Adverse Events), Maximum Tolerated Dose at 28 days and 1 more. Started May 2022; status: completed.
02
Drugs
lirodegimod
03
Conditions
non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)large granular lymphocytic leukemia (LGLL)T-cell prolymphocytic leukemia (T-PLL)solid tumor
Beyond the preview
Go deeper on NCT05225584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05225584.